Mouse EPO protein (Recombinant) (STJP000374)

SKU:
STJP000374

Current Stock:
Host: HEK293
Note: STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Mouse EPO-protein was developed from hek293. For use in research applications.
Conjugation: Unconjugated
Formulation: Lyophilised from 0.2 µm filtered PBS solution pH7.4.
Dilution Range: Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers.
Storage Instruction: The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA
Endotoxin: Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA
Immunoreactivity: The activity was determined by its ability to bind in functional ELISA assay. NA
Gene Symbol: Epo
Gene ID: 13856
Uniprot ID: EPO_MOUSE
Immunogen Region: Mature chain
Immunogen: DNA sequence encoding the mature chain of Mouse erythropoietin EPO including a C-terminal His tag was expressed in HEK293 Cells. NA
Immunogen Sequence: APPRLICDSR VLERYILEAK EAENVTMGCA EGPRLSENIT VPDTKVNFYA WKRMEVEEQA IEVWQGLSLL SEAILQAQAL LANSSQPPET LQLHIDKAIS GLRSLTSLLR VLGAQKELMS PPDTTPPAPL RTLTVDTFCK LFRVYANFLR GKLKLYTGEV NA
Tissue Specificity Produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals.
Function Hormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.
Protein Name Erythropoietin
Database Links Reactome: R-MMU-9027276
Reactome: -MMU-9027284
Cellular Localisation Secreted
Alternative Protein Names Erythropoietin protein
Epo protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance